Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Birinyi

Neurological Surgery Alexandria, LA Medical Doctor

NPI 1851603906 CMS profile 311480

233 Pecan Park Ave Ste D, Ste D, Alexandria, LA 71303

Open in the dashboard

General payments

$7,564

72 records reported · program years 2019–2025

Research payments

$1,000

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Birinyi of Alexandria, LA is reported in the CMS Open Payments database as having received $7,564 across 72 general payments and $1,000 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $154 3
2024 General $342 4
2023 General $663 8
2022 General $748 13
2021 General $4,033 20
2021 Research $1,000 1
2020 General $532 10
2019 General $1,092 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Birinyi
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Paul Birinyi were reported at $154. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Paul Birinyi Neurological Surgery median Middle half National median
2019 $1,092 $582 $138–$3,006 $163
2020 $532 $294 $76–$2,174 $114
2021 $4,033 $387 $105–$2,432 $132
2022 $748 $542 $139–$2,989 $149
2023 $663 $534 $145–$2,697 $160
2024 $342 $574 $155–$3,046 $164
2025 $154 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Globus Medical, Inc. $2,607 19 payments
  2. CTL Medical Corporation $2,236 9 payments
  3. Orthofix Medical, Inc. $912 7 payments
  4. Eminent Spine, LLC $290 1 payment
  5. Seaspine Orthopedics Corporation $179 3 payments
  6. Medtronic, Inc. $173 4 payments
  7. GS Solutions, Inc. $137 2 payments
  8. RTI Surgical, Inc. $116 1 payment
  9. Siemens Medical Solutions USA, Inc. $109 1 payment
  10. Bioventus LLC $102 1 payment
  11. Other $703 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,105 17 payments
  2. Food and Beverage $2,459 51 payments
  3. Consulting Fee $2,000 4 payments
Products named General payments · program years 2019–2025
  1. Spinal $2,166 8 payments
  2. Spine $916 1 payment
  3. M6-C Artificial Cervical Disc $912 7 payments
  4. Excelsius Robotics System $479 4 payments
  5. ExcelsiusGPS Robotic Navigation System $391 2 payments
  6. ELSA $286 3 payments
  7. RISE-L $247 1 payment
  8. EXCELSIUS GPS $124 1 payment
  9. FORTILINK-C IBF SYSTEM $116 1 payment
  10. Cios Alpha $109 1 payment
  11. Other $1,379 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. GS Solutions, Inc. $1,000 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

146

Median for Neurosurgery: 83

Drug cost

$1,468

Median for Neurosurgery: $872

Branded share of claims

50%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 58 $715
Cyclobenzaprine Hcl Generic 17 $426
Gabapentin Generic 25 $180
Methocarbamol Generic 19 $106
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 15 $25
Tramadol Hcl Generic 12 $16

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$107,483

Medicare's payments for the services billed

Medicare patients

229

Average age 76

Services billed

543

126 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 41%
Ischemic heart disease 37%
Diabetes 35%
Osteoporosis 34%
Chronic kidney disease 32%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

73 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record